EyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu

Dow Jones

2024-10-29

By Sabela Ojea

Shares of EyePoint Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema.

The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year.

The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial.

Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health.

The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

October 28, 2024 12:00 ET (16:00 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2479436396"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479436396\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2479436396?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-29 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479436396","market":"sg","top_or_hot":-1,"title":"EyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema. \n</p>\n<p>\n  The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year. \n</p>\n<p>\n  The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial. \n</p>\n<p>\n  Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health. \n</p>\n<p>\n  The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2024 12:00 ET (16:00 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>EyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for Duravyu\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-10-29 00:00</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/EYPT\">EyePoint</a> Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema. \n</p>\n<p>\n  The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year. \n</p>\n<p>\n  The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial. \n</p>\n<p>\n  Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health. \n</p>\n<p>\n  The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2024 12:00 ET (16:00 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EYPT","symbol_name":"EyePoint","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479436396","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479436396","pubTimestamp":1730131200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of EyePoint Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema.The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year.The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial.Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health.The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EYPT":"EyePoint"},"translate_title":"Duravyu临床试验数据积极，EyePoint Pharmaceuticals股价上涨35%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYPT":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of EyePoint Pharmaceuticals climbed after the company said it received positive 16-week interim data for its Verona clinical trial evaluating Duravyu in patients with diabetic macular edema. \n\n\n  The stock was up 35% to $12.84 in Monday morning trading. Shares have fallen 44% this year. \n\n\n  The developer of treatments for retinal diseases said Duravyu demonstrated early, sustained, and clinically meaningful improvement in best-corrected visual acuity during clinical trial. \n\n\n  Diabetic macular edema is manifested as retinal thickening caused by the accumulation of intraretinal fluid, according to the National Institutes of Health. \n\n\n  The company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2024 12:00 ET (16:00 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}